{"protocolSection":{"identificationModule":{"nctId":"NCT01028053","orgStudyIdInfo":{"id":"GE-067-005"},"organization":{"fullName":"GE Healthcare","class":"INDUSTRY"},"briefTitle":"Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease","officialTitle":"A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease"},"statusModule":{"statusVerifiedDate":"2014-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-12"},"primaryCompletionDateStruct":{"date":"2014-01","type":"ACTUAL"},"completionDateStruct":{"date":"2014-01","type":"ACTUAL"},"studyFirstSubmitDate":"2009-12-07","studyFirstSubmitQcDate":"2009-12-08","studyFirstPostDateStruct":{"date":"2009-12-09","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-07-30","resultsFirstSubmitQcDate":"2014-09-03","resultsFirstPostDateStruct":{"date":"2014-09-11","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-09-03","lastUpdatePostDateStruct":{"date":"2014-09-11","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GE Healthcare","class":"INDUSTRY"},"collaborators":[{"name":"Medpace, Inc.","class":"INDUSTRY"},{"name":"i3 Statprobe","class":"INDUSTRY"},{"name":"i3 Research","class":"INDUSTRY"},{"name":"Quintiles, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease."},"conditionsModule":{"conditions":["Mild Cognitive Impairment","Alzheimer's Disease"],"keywords":["Mild Cognitive Impairment","Positron Emission Tomography","National Institute of Neurological and Communicative Disorders and Stroke","Alzheimer's Disease and Related Disorders Association","Assess Prognostic Usefulness of Flutemetamol Injection for Identifying Subjects who will Convert to Clinically Probable Alzheimer's Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":365,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Flutemetamol (18F) Injection","type":"EXPERIMENTAL","description":"Flutemetamol (18F) Injection","interventionNames":["Drug: Flutemetamol (18F) Injection"]}],"interventions":[{"type":"DRUG","name":"Flutemetamol (18F) Injection","description":"All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.","armGroupLabels":["Flutemetamol (18F) Injection"],"otherNames":["Flutemetamol","18F"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.","description":"Visual Interpretation of the PET scan by independent readers.\n\nNote: The statistic Hazard ratio (HR) is the ratio of the hazard rates in the 2 groups (1 group being normal (negative for amyloid B) and 1 group being abnormal (positive for amyloid B). Under the null hypothesis of equal rates, the HR would be equal to 1.\n\nAs the HR increases above 1, the chances of being probable Alzheimer's Disease (pAD) also increases.\n\nNote: Eight Subjects who withdrew prior to the first Clinical Adjudication Committee (CAC) evaluation are not included in the analysis. (232 - 8 = 224 Subjects included).","timeFrame":"Up to 36 months post flutemetamol administration"}],"secondaryOutcomes":[{"measure":"The of Normal and Abnormal Subjects Who Convert to Probable Alzheimer's Disease (pAD) Within the Follow up Period.","description":"Numbers of subjects with normal and abnormal patterns of \\[18F\\]flutemetamol uptake who converted to pAD.","timeFrame":"Up to 36 months post flutemetamol administration."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The subject is 60 years old or older.\n* The subject meets the Petersen criteria for amnestic MCI.\n* The subject has a score of less than or equal to 4 on the Modified Hachinski Ischemic Scale.\n* The subject has a MMSE score of 24-30.\n* The subject has a non-contrast MRI examination as part of the screening visit that excludes aMCI arising from structural causes.\n* The subject and/or the subject's legally acceptable representative, if applicable, in accordance with local regulations, has signed and dated an informed consent.\n\nExclusion Criteria:\n\n* The subject has any significant neurologic disease other than suspected aMCI; such as Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities.\n* The subject has one or more aneurysm clips, artificial heart valves, metal implants, embedded metal fragments or pacemakers that would pose a risk during an MRI.\n* The subject has major depression, bipolar disorder, as described in the DSM-IV within the past year.\n* The subject has history of schizophrenia (DSM-IV criteria).\n* The subject has had, within the prior 3 months, psychotic features, agitation or behavioral problems that could lead to protocol compliance issues.","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Paul Sherwin, M.D.","affiliation":"GE Healthcare","role":"STUDY_CHAIR"}],"locations":[{"facility":"GE Healthcare","city":"Princeton","state":"New Jersey","zip":"08540","country":"United States","geoPoint":{"lat":40.34872,"lon":-74.65905}}]},"referencesModule":{"references":[{"pmid":"35351181","type":"DERIVED","citation":"Pichet Binette A, Palmqvist S, Bali D, Farrar G, Buckley CJ, Wolk DA, Zetterberg H, Blennow K, Janelidze S, Hansson O. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. Alzheimers Res Ther. 2022 Mar 29;14(1):46. doi: 10.1186/s13195-022-00990-0."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Flutemetamol (18F) Injection","description":"Flutemetamol (18F) Injection: All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"365"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"232"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"133"}]}],"dropWithdraws":[{"type":"Screen Failure","reasons":[{"groupId":"FG000","numSubjects":"113"}]},{"type":"Patient Request","reasons":[{"groupId":"FG000","numSubjects":"11"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Technical Problem","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Terminated by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Various reasons","reasons":[{"groupId":"FG000","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Flutemetamol (18F) Injection","description":"Flutemetamol (18F) Injection: All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"232"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71.1","spread":"8.62"}]}]}]},{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"63"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"169"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"118"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"114"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"109"}]}]},{"title":"Belgium","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]},{"title":"Denmark","categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]},{"title":"Finland","categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}]},{"title":"Sweden","categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]},{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"80"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.","description":"Visual Interpretation of the PET scan by independent readers.\n\nNote: The statistic Hazard ratio (HR) is the ratio of the hazard rates in the 2 groups (1 group being normal (negative for amyloid B) and 1 group being abnormal (positive for amyloid B). Under the null hypothesis of equal rates, the HR would be equal to 1.\n\nAs the HR increases above 1, the chances of being probable Alzheimer's Disease (pAD) also increases.\n\nNote: Eight Subjects who withdrew prior to the first Clinical Adjudication Committee (CAC) evaluation are not included in the analysis. (232 - 8 = 224 Subjects included).","populationDescription":"Eight Subjects who withdrew prior to the first Clinical Adjudication Committee (CAC) evaluation are not included in the analysis. (232 - 8 = 224 Subjects included).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Ratio of visual interpretations","timeFrame":"Up to 36 months post flutemetamol administration","groups":[{"id":"OG000","title":"Hazard Ratio","description":"The statistic Hazard ratio (HR) is the ratio of the hazard rates in the 2 groups (1 group being normal (negative for amyloid B) and 1 group being abnormal (positive for amyloid B). Under the null hypothesis of equal rates, the HR would be equal to 1.\n\nAs the HR increases above 1, the chances of being probable Alzheimer's Disease (pAD) also increases."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"}]}],"classes":[{"title":"Reader 1 - Visual Interpretation","categories":[{"measurements":[{"groupId":"OG000","value":"3.418"}]}]},{"title":"Reader 2 - Visual Interpretation","categories":[{"measurements":[{"groupId":"OG000","value":"1.962"}]}]},{"title":"Reader 3 - Visual Interpretation","categories":[{"measurements":[{"groupId":"OG000","value":"2.561"}]}]},{"title":"Reader 4 - Visual Interpretation","categories":[{"measurements":[{"groupId":"OG000","value":"2.633"}]}]},{"title":"Reader 5 - Visual Interpretation","categories":[{"measurements":[{"groupId":"OG000","value":"2.580"}]}]}]},{"type":"SECONDARY","title":"The of Normal and Abnormal Subjects Who Convert to Probable Alzheimer's Disease (pAD) Within the Follow up Period.","description":"Numbers of subjects with normal and abnormal patterns of \\[18F\\]flutemetamol uptake who converted to pAD.","populationDescription":"Eight Subjects who withdrew prior to the first Clinical Adjudication Committee (CAC) evaluation are not included in the analysis. (232 - 8 = 224 Subjects included).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of subjects","timeFrame":"Up to 36 months post flutemetamol administration.","groups":[{"id":"OG000","title":"Not Clinically Probable Alzheimer's Disease","description":"A blinded visual interpretation of a clinical diagnosis of the number of Normal-Scan and Abnormal-Scan Subjects who Converted to not clinically probable Alzheimer's Disease (pAD)."},{"id":"OG001","title":"Clinically Probable Alzheimer's Disease","description":"A blinded visual interpretation of a clinical diagnosis of the number of Normal-Scan and Abnormal-Scan Subjects who Converted to clinically probable Alzheimer's Disease (pAD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"81"}]}],"classes":[{"title":"Reader 1 - Normal","categories":[{"measurements":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"31"}]}]},{"title":"Reader 1 - Abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"50"}]}]},{"title":"Reader 2 - Normal","categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"21"}]}]},{"title":"Reader 2 - Abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"60"}]}]},{"title":"Reader 3 - Normal","categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"37"}]}]},{"title":"Reader 3 - Abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"44"}]}]},{"title":"Reader 4 - Normal","categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"28"}]}]},{"title":"Reader 4 - Abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"53"}]}]},{"title":"Reader 5 - Normal","categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"29"}]}]},{"title":"Reader 5 - Abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"52"}]}]},{"title":"Majority Reads - Normal","categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"29"}]}]},{"title":"Majority Reads - Abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"52"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Flutemetamol (18F) Injection","description":"Flutemetamol (18F) Injection: All subjects will receive an intravenous dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.","seriousNumAffected":1,"seriousNumAtRisk":232,"otherNumAffected":0,"otherNumAtRisk":232}],"seriousEvents":[{"term":"Anaphylactoid Reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":232}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Paul Sherwin M.D.","organization":"GE Healthcare","email":"Paul.Sherwin@ge.com","phone":"16095146820"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000000544","term":"Alzheimer Disease"},{"id":"D000060825","term":"Cognitive Dysfunction"}],"ancestors":[{"id":"D000003704","term":"Dementia"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000024801","term":"Tauopathies"},{"id":"D000019636","term":"Neurodegenerative Diseases"},{"id":"D000019965","term":"Neurocognitive Disorders"},{"id":"D000001523","term":"Mental Disorders"},{"id":"D000003072","term":"Cognition Disorders"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M29395","name":"Cognitive Dysfunction","asFound":"Mild Cognitive Impairment","relevance":"HIGH"},{"id":"M3575","name":"Alzheimer Disease","asFound":"Alzheimer's Disease","relevance":"HIGH"},{"id":"M6064","name":"Communication Disorders","relevance":"LOW"},{"id":"M6594","name":"Dementia","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M22692","name":"Tauopathies","relevance":"LOW"},{"id":"M21248","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M21526","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M5991","name":"Cognition Disorders","relevance":"LOW"},{"id":"T2192","name":"Familial Alzheimer Disease","asFound":"Alzheimer's Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000581552","term":"Flutemetamol"}],"ancestors":[{"id":"D000019275","term":"Radiopharmaceuticals"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M263464","name":"Flutemetamol","asFound":"Syringe pump","relevance":"HIGH"},{"id":"M20948","name":"Radiopharmaceuticals","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}